Article Text

Download PDFPDF

P-019 The Plavix Conundrum: Determining Who Will Respond to Plavix
  1. A Paul,
  2. J Dalfino,
  3. J Yamamoto,
  4. A Boulos
  1. Department of Neurosurgery, Albany Medical Center, Albany, NY


Introduction There has been increasing use of dual antiplatelet therapy in neuroendovascular procedures due to the advent of more versatile stents and flow diverters. The cardiac literature suggests that approximately 30% of patients are resistant to Plavix. Multiple studies have suggested that an inappropriate response to Plavix is related to increased risk of embolic complication. Predicting which patients will respond to Plavix would be beneficial and time saving, particularly in urgent scenarios. We sought to determine if there were any factors which could predict responsiveness to Plavix therapy.

Materials and methods We conducted a retrospective analysis of 82 patients who were started on aspirin and Plavix dual therapy in preparation for placement of stent placement for aneurysm treatment. A chart review was conducted in order to determine lab values. A PRU ≤ 170 was defined as a Plavix responder.

Results 82 patients who had been started on aspirin and Plavix dual therapy were identified. Seven patients were loaded for an urgent procedure and these patients were excluded from the remainder of the evaluation. Twenty three (31%) of patients were found to be resistant to Plavix with a PRU > 170 and nine patients (12%) were found to be hyperresponsive (PRU < 40). Women were three times more likely to be nonresponders when compared to men (35% vs 11%, p = 0.05). There was no difference in hyperresponsiveness between the two genders (11% vs 17% (p = 0.7)).

Prior cardiac studies have suggested that a larger mean platelet volume (MPV) may be associated with Plavix nonresponsiveness. This cohort was divided into quartiles based on the MPV prior to Plavix administration. The average PRU increased as the MPV increased between the quartiles (Figure 1).

Abstract P-019 Figure 1

Average PRU among the MPV quartiles. The dotted line represents a therapeutic PRU of 170

A subgroup of female patients was then further analyzed in order to determine if any value was predictive of platelet responsiveness. A MPV prior to Plavix initiation of ≥10.0 was found to be associated with Plavix nonresponsiveness. Five of 23 patients (22%) who had a MPV < 10.0 were found to be nonresponders compared to 12 of 22 patients (55%) who had a MPV ≥ 10.0 (p = 0.03) (Figure 2).

Abstract P-019 Figure 2

A bar graph depicting nonresponders and responders to Plavix separated by MPV

Conclusion Determining which factors play a role in plavix responsiveness will become more essential to the endovascular neurosurgeon as a wide variety of stents continue to be used. This data suggests that women are more likely than men to be nonresponders (35% vs 11%, p = 0.05) and that a MPV ≥ 10.0 was associated with nonresponsiveness. Larger studies are needed however it may be reasonable to consider starting an alternative antiplatelet agent in female patients with MPV ≥ 10.0 in urgent situations.

Disclosures A. Paul: None. J. Dalfino: None. J. Yamamoto: None. A. Boulos: None.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.